Compare Fox Corp Class A (FOXA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Fox Corp Class A trades at $62.63 (market cap $24.79B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Fox Corp Class A is far larger — about 25.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Fox Corp Class A pays a 0.93% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 35 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FOXA | MRVI | |
|---|---|---|
Market Cap | $24.79B | $977.37M |
Volume | 2,972,036 | 2,742,564 |
Sector | Media | Health |
52-Week High | $76.11 | $9.00 |
52-Week Low | $48.79 | $2.83 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $28.16B | $1.08B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.50, down slightly by 0.14% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate. Revenue grew to $16.30 billion in 2025, and net income reached $2.26 billion. Analysts maintain a bullish consensus with a $72.00 price target, though the pending $22 billion Roku acquisition faces extended DOJ scrutiny, a key near-term focus.
The outlook for FOXA is cautiously optimistic, supported by solid fundamentals and analyst confidence, but weighed by regulatory risks from the Roku deal and a projected earnings dip in 2026. Investment appeal lies in valuation metrics like a P/E of 16.2 and robust cash flow, though investors must monitor deal approval progress and competitive pressures in media.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
